Dizon Brian L P, Holla Prasida, Mutic Evan C, Schaughency Paul, Pierce Susan K
Rheumatology Fellowship Training Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
NPJ Vaccines. 2025 May 14;10(1):96. doi: 10.1038/s41541-025-01133-w.
In an era of predicted emerging pandemics, the production of effective vaccines may require an in-depth understanding of the biology of human naive B (B) cells. Here we provide evidence that the majority of B cells expressed CD73, an ecto-5'-nucleotidase often associated with immune cell suppression, and demonstrated features of anergy, including an IgMIgD surface phenotype, reduced calcium flux in response to IgM crosslinking, and increased PTEN expression. Analysis of antibody sequences encoded by the inherently autoreactive V4-34 heavy chain produced by plasmablasts seven days following influenza vaccination showed that in younger but not in older individuals, anergic B cells provided a reservoir of B cells capable of responding to vaccination by somatic mutation, resulting in diversification and loss of autoreactivity. These results suggest that effective human vaccines may require the ability to awaken or 'redeem' anergic B cells that can be repurposed to participate in pathogen-specific responses.
在一个预计会出现新的大流行疾病的时代,生产有效的疫苗可能需要深入了解人类初始B(B)细胞的生物学特性。在这里,我们提供的证据表明,大多数B细胞表达CD73,这是一种通常与免疫细胞抑制相关的胞外5'-核苷酸酶,并表现出无反应性的特征,包括IgM IgD表面表型、对IgM交联反应的钙通量降低以及PTEN表达增加。对流感疫苗接种七天后浆母细胞产生的固有自身反应性V4-34重链编码的抗体序列分析表明,在年轻个体而非老年个体中,无反应性B细胞提供了一个B细胞库,这些B细胞能够通过体细胞突变对疫苗接种做出反应,从而导致自身反应性的多样化和丧失。这些结果表明,有效的人类疫苗可能需要唤醒或“挽救”无反应性B细胞的能力,这些细胞可以被重新利用以参与病原体特异性反应。